Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
Events next week:
It is still fairly quiet in the IPO space but Hong Kong's pipeline is swelling, likely heading for a very busy 4Q 2021. SenseTime, ClouDr, 58 Freight (GogoX), and Samoyed Cloud are the notable new filings this week.
Our Hong Kong IPO coverage this week was skewed towards Healthcare and Biotech companies. We initiated on Imeik Technology Development (300896 CH) (A/H listing), Ambio Pharmaceuticals (ABP HK), Jenscare Scientific (JCS HK), and Dingdang Health Technology Group (DDH HK) .
We also shared our initial thoughts on Helen's International and Simplex IPOs in Hong Kong and Japan, respectively. The former had been pre-marketing this week, and likely to launch its IPO bookbuild next week while the latter will open books the week after on 7th September.
In India, we initiated on Aditya Birla Sun Life AMC (570499Z IN) which was approved by SEBI earlier this month.
However, recent Indian IPOs have failed to perform. CarTrade (CARTRADE IN) , Aptus Value Housing Finance India (APTUS IN), Nuvoco Vistas (NUVOCO IN) broke their respective IPO prices, mostly due to unattractive valuation.
Back in Korea, Hyundai Heavy Industries (1748326D KS) opened its books on Thursday and was reported to have been covered a day later. We didn't think there is upside for the IPO based on valuation. On top of that, Korean shipbuilders have been trading weak lately, compared to Chinese shipbuilders. Books will close on Friday, 3rd September and it is expected to list on 16th September.
It was another busy week for placements. Some are long-dated; Activia Properties and Showa Denko will price on 1st and 6th September while OBIC, which we covered last week will price on Tuesday, 31st August.
Our overall accuracy rate is 74% for IPOs and 67.6% for Placements
(Performance measurement criteria is explained at the end of the note)
Hong Kong/China
US/China ADRs
India
Japan/Korea
Others
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.